Q4 2024 Celcuity Inc Earnings Call Transcript
Key Points
- Celcuity Inc (CELC) completed enrollment of the PIK3CA wild-type cohort in their VIKTORIA-1 Phase III study, marking significant progress in their clinical development programs.
- The company has selected approximately 200 sites for the VIKTORIA-2 Phase III study, indicating strong interest and support for their research initiatives.
- Preliminary data from the Phase Ib study showed that gedatolisib was equally potent in cell lines with and without PIK3CA mutations, suggesting broad efficacy potential.
- Gedatolisib demonstrated a favorable safety profile with a low treatment-related discontinuation rate of 4% in the Phase Ib study, which is promising compared to other treatments.
- Celcuity Inc (CELC) ended the year with a strong cash position of approximately $235.1 million, providing financial stability to support ongoing and future research activities.
- Celcuity Inc (CELC) reported a significant increase in net loss for the fourth quarter and full year 2024, with a net loss of $36.7 million for Q4 and $111.8 million for the full year.
- Research and development expenses increased substantially, reaching $104.2 million for the full year 2024, which may impact financial sustainability if not offset by future revenues.
- The company faces competition in the evolving treatment landscape for HR+, HER2-negative advanced breast cancer, with several investigational therapies under development.
- There is uncertainty regarding the timing of achieving the required number of events for the VIKTORIA-1 study, which could delay data readouts and subsequent regulatory filings.
- Celcuity Inc (CELC) anticipates entering a quiet period ahead of top line data release, which may limit communication and updates to investors during this critical phase.
Good afternoon, ladies and gentlemen, and welcome to the Celcuity fourth quarter and full year 2024 financial results webcast conference call. (Operator Instructions) I would now like to turn the conference over to Apoorva Chaloori with ICR Healthcare. Please go ahead.
Thank you, operator, and good afternoon to everyone on the call. Thank you for joining us to review Celcuity's fourth quarter and full year 2024 financial results and business update. Earlier today, Celcuity released financial results for the fourth quarter ending December 31, 2024. The press release can be found on the Investors section of the website.
Joining me on the call today are Brian Sullivan, Celcuity's Chief Executive Officer, and Co-Founder; Vicky Hahne, Chief Financial Officer; as well as Igor Gorbatchevsky, Chief Medical Officer, who will be available during Q&A.
Before we begin, I would like to remind listeners that our comments today will include some forward-looking statements. These statements involve a number of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
